Canaccord Genuity Reiterates a 'Buy' on Amicus Therapeutics (FOLD); Management Dinner Takeaways
Tweet
Share
E-mailGet Alerts FOLD Hot Sheet
Price: $14.49 --0%
Rating Summary:
12 Buy, 9 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Rating Summary:
12 Buy, 9 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Amicus Therapeutics (NASDAQ: FOLD) price target of $10.00.
Analyst, Ritu Baral, said, "Migalastat: two separate clinical programs with distinct decoupled clinical benefit and development risk profiles. We hosted a dinner with FOLD management where discussion focused on migalastat monoTx and comboTx programs. In monoTx, migalastat must reach the cytoplasm, where it binds to and chaperones a patient’s own mutated enzyme into the lysosome. In comboTx, the drug binds and stabilizes ERT enzyme in the plasma. We think each approach has distinct potential clinical benefit and development risk/challenges, decoupling the risk profiles of monoTx and comboTx trials."
"We think Q3/12 pivotal Fabry monoTx ‘011 trial data for migalastat (f.k.a. Amigal) will be a strong positive, transformational catalyst. We think ‘011 has a high chance of success on Phase 2 precedent and trial enrichment."
For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.
Shares of Amicus Therapeutics closed at $6.00 yesterday.
Analyst, Ritu Baral, said, "Migalastat: two separate clinical programs with distinct decoupled clinical benefit and development risk profiles. We hosted a dinner with FOLD management where discussion focused on migalastat monoTx and comboTx programs. In monoTx, migalastat must reach the cytoplasm, where it binds to and chaperones a patient’s own mutated enzyme into the lysosome. In comboTx, the drug binds and stabilizes ERT enzyme in the plasma. We think each approach has distinct potential clinical benefit and development risk/challenges, decoupling the risk profiles of monoTx and comboTx trials."
"We think Q3/12 pivotal Fabry monoTx ‘011 trial data for migalastat (f.k.a. Amigal) will be a strong positive, transformational catalyst. We think ‘011 has a high chance of success on Phase 2 precedent and trial enrichment."
For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.
Shares of Amicus Therapeutics closed at $6.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lowe's (LOW) PT Lowered to $275 at Guggenheim
- CrowdStrike (CRWD) PT Lowered to $227 at Scotiabank
- MDxHealth SA (MDXH) PT Lowered to $2 at BTIG
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
